KFAS
AQST icon

Keating Financial Advisory Services’s Aquestive Therapeutics AQST Stock Holding History

Keating Financial Advisory Services’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.3K Buy
12,563
+1
+0% +$4 0.01% 673
2026
Q1 		$52.1K Sell
12,562
-263
-2% -$1.07K 0.01% 608
2025
Q4 		$82.8K Buy
+12,825
New +$79.9K 0.01% 543

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Keating Financial Advisory Services's AQST Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Aquestive Therapeutics (AQST) stake by 0.01% in Q2 2026, buying an estimated $4 and bringing the position to 12,563 shares worth $52.3K. The position accounts for 0.01% of the portfolio, ranked #673.

Keating Financial Advisory Services first reported a position in AQST in Q4 2025 and has held it in 3 quarters since. The position peaked at $82.8K in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Keating Financial Advisory Services held 12,563 shares of Aquestive Therapeutics worth $52.3K as of Q2 2026.
  • Keating Financial Advisory Services bought 1 Aquestive Therapeutics share in Q2 2026, an estimated $4.
  • Aquestive Therapeutics made up 0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #673 holding.
  • Keating Financial Advisory Services first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Aquestive Therapeutics position peaked at $82.8K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.